...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer >Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study
【24h】

Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study

机译：口腔冷冻疗法对产物造血干细胞移植治疗同种异体造血干细胞移植的患者：预期随机研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose To explore the best schedule of oral cryotherapy for the prevention of oral mucositis in recipients of myeloablative hematopoietic stem cell transplantation (HSCT). Methods A prospective randomized study was conducted to recruit allogeneic HSCT recipients, who were then randomly allocated into four arms to accept the following: oral cryotherapy during the whole course (arm A) or second half of the course (arm B) of cytotoxic agents administration, regular oral cryotherapy twice a day (arm C), or conventional oral care without cryotherapy (arm D). Status of oral mucositis was daily assessed from the first day of conditioning to the 15th day post-HSCT. A myeloablative conditioning regimen was used which was composed of busulfan, cyclophosphamide, and cytarabine. Results Totally 160 cases were consecutively enrolled in this study, and 145 cases were eligible for oral mucositis assessment. Both arm A and arm B were associated with a lower incidence and short duration of severe mucositis (>= grade 3), although no statistical difference was found between these two groups (p = 0.463, p = 0.678). The highest incidence of severe mucositis was observed in arm C. Recovery of mucositis also had a significant diversity among the 4 arms (F = 4.133, p = 0.008). Conclusions Risk and outcome of severe oral mucositis could be ameliorated by oral cryotherapy during the administration of cytotoxic agents for allogeneic HSCT patients receiving non-radiation myeloablative conditioning regimen, and a half-course schedule could acquire a comparable efficacy compared with the whole-course schedule.
机译：目的是探索肌瘤造血干细胞移植受者（HSCT）预防口腔粘膜炎的最佳口腔冷冻疗法计划。方法对预期随机化研究进行招募同种异体的HSCT接受者，然后将其随机分配给四个武器，接受以下内容：口腔冷冻疗法在整个课程（ARM A）或细胞毒性药剂施用的过程（ARM B）的下半部分，常规口服冷冻疗法每天两次（ARM C），或常规口腔护理而不冷冻疗法（ARM D）。口腔粘膜炎的状态每天从调理后的第15天后的第15天评估。使用了由伯氟甘蔗，环磷酰胺和红糖组成的髓鞘调节方案。结果本研究共纳160例，145例符合口服粘膜炎评估。臂A和ARM B都与较低的发生率和严重粘膜炎（> = 3级）的持续时间较低相关，尽管在这两组之间没有发现统计差异（P = 0.463，P = 0.678）。在ARM C中观察到严重粘膜炎的最高发病率。粘液炎的回收率在4个臂中也具有显着的多样性（f = 4.133，p = 0.008）。结论严重口腔粘膜炎的风险和结果可能通过口服冷冻治疗，用于治疗非基因HSCT患者的细胞毒性药物，接受非辐射髓鞘调理方案，与全程时间表相比，半课程表可以获得可比疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号